Intraductal carcinoma of the prostate: Precursor or aggressive phenotype of prostate cancer?

The Prostate ◽  
2012 ◽  
Vol 73 (4) ◽  
pp. 442-448 ◽  
Author(s):  
Helmut Bonkhoff ◽  
Thomas M. Wheeler ◽  
Theodorus H. van der Kwast ◽  
Cristina Magi-Galluzzi ◽  
Rodolfo Montironi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Intraductal Carcinoma ◽  
Aggressive Phenotype ◽  
Carcinoma Of The Prostate

The presence of intraductal carcinoma of the prostate in needle biopsy as a prognostic parameter for prostate cancer patients with distant metastasis.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 237-237
Author(s):  
Masashi Kato ◽  
Toyonori Tsuzuki ◽  
Kyosuke Kimura ◽  
Naoto Sassa ◽  
Yasushi Yoshino ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Needle Biopsy ◽  
Univariate Analysis ◽  
Intraductal Carcinoma ◽  
Prognostic Parameter ◽  
Carcinoma Of The Prostate ◽  
The Core ◽  
Gleason Pattern

237 Background: The presence of intraductal carcinoma of the prostate (IDC-P) is an adverse prognostic factor for prostate-specific antigen (PSA) failure, progression-free survival, and cancer-specific survival (CSS) in localized prostate cancer patients. However, there is no data indicating whether the presence of IDC-P can influence outcome in prostate cancer patients with distant metastasis at presentation. We aimed to evaluate whether IDC-P in needle biopsies is also an adverse prognostic parameter for CSS in prostate cancer patients with distant metastasis. Methods: We retrospectively evaluated 159 prostate cancer patients with distant metastasis who presented at the hospitals that the authors are affiliated with between 2002 and 2012 and reviewed the slides prepared from prostate needle biopsy specimens. Data on the patient age, performance status, clinical T stage, serum PSA, C-reactive protein, alkaline phosphatase (ALP), hemoglobin (Hb), albumin, serum calcium, biopsy Gleason score (> 8 or not), the presence of Gleason pattern 5, the percent of the core involved with cancer, and the maximum percent of a core involved with cancer were analyzed. Patient characteristics were analyzed using the Fisher's exact test. Multivariate Cox proportional hazard regression models were developed to predict CSS. Results: Patient median age was 73 years (range 47–90 years). The median serum PSA was 290 ng/mL (range 4.18–10,992 ng/mL). The median follow-up period was 36 months (range 3–120 months). IDC-P component was detected in 103 (64.8%) patients. There were 82 patients who died of the disease and 6 patients who died of other causes. Using univariate analysis, IDC-P (p = 0.0001), the presence of Gleason pattern 5 (p = 0.005), the percent of the core involved with cancer (p = 0.002), Hb (p = 0.001), and high ALP (p = 0.002) were all shown to be significantly associated with CSS. In the multivariate analysis, only IDC-P (p = 0.016; hazard ratio, 2.187) was significantly associated with CSS. Conclusions: The presence of IDC-P in needle biopsy is a prognostic parameter for CSS in patients with distant metastasis at presentation.

1121 INTRADUCTAL CARCINOMA OF THE PROSTATE CAN BE A STRONG PREDICTOR OF PROSTATE CANCER DEATH

2012 ◽  
Vol 187 (4S) ◽  
Author(s):  
Masashi Kato ◽  
Kyosuke Kimura ◽  
Toyonori Tsuzuki ◽  
Ryohei Hattori ◽  
Momokazu Gotoh
Keyword(s):  
Prostate Cancer ◽  
Strong Predictor ◽  
Intraductal Carcinoma ◽  
Cancer Death ◽  
Carcinoma Of The Prostate ◽  
Prostate Cancer Death

Presence of intraductal carcinoma of the prostate on needle biopsy as a prognostic factor for prostate cancer in radical prostatectomy patients.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 268-268
Author(s):  
Masashi Kato
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Needle Biopsy ◽  
Univariate Analysis ◽  
Intraductal Carcinoma ◽  
Carcinoma Of The Prostate ◽  
High Risk Prostate Cancer ◽  
Gleason Pattern ◽  
Risk Prostate Cancer

268 Background: Intraductal carcinoma of the prostate (IDCP) is seen with widely invasive, biologically aggressive prostate cancer. A recent study has shown this morphologic pattern is useful for prognostication of biochemical recurrence after radical prostatectomy, whereas there is no paper to report biopsy finding of IDCP to be a positive predictor of progression-free survival (PFS) and cancer-specific survival (CSS). Methods: This retrospective study included men with high-risk prostate cancer treated with radical prostatectomy between 1991 and 2005, and we reviewed slides of biopsy samples. Presence of IDCP was defined using previously published diagnostic criteria by a single genitourinary pathologist. Analyzed factors included age, prostate-specific antigen (PSA), clinical T stage, higher biopsy Gleason score (bGS), presence of Gleason pattern five, and IDCP on biopsy samples. Finally, a total of 205 patients with high-risk prostate cancer were entered in our retrospective clinicopathological analysis. Results: Patient mean age was 68. Baseline characteristics included a PSA greater than 20 ng/ml at diagnosis in 122 cases (60%), clinical stage greater than T2 (cT) in 86 (42%), and bGS ³a8 in 150 (73%) in all patients. Follow-up period was 86 months on average. The presence of IDCP on needle biopsy was in 75 (37%). Forty-four patients showed clinical failure, and 20 patients died of the disease. Patients with IDCP showed a higher increased PSA level, higher increased bGS, and more advanced cT than those without IDCP (p < 0.0001). In univariate analysis, IDCP (p < 0.0001), cT (p < 0.0001), bGS (p = 0.0002), and presence of Gleason pattern five (p=0.004) were significantly associated with PFS; IDCP (p < 0.001) and cT (p = 0.02) were significantly associated with CSS. In multivariate analysis, IDCP (p< 0.0001; hazard ratio (HR), 3.574) and cT (p= 0.004; HR, 3.087) were significantly associated with PFS; IDCP (p = 0.001; HR, 8.405) and PSA level (p = 0.0044; HR, 2.920) were significantly associated with CSS. Conclusions: Presence of IDCP on needle biopsy can be a significant predictor of PFS and CSS when analyzing factors of biopsy samples in high risk prostate cancer.

Efficacy of docetaxel and androgen receptor axis-targeted agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 150-150
Author(s):  
Akiyuki Yamamoto ◽  
Masashi Kato ◽  
Toyonori Tsuzuki ◽  
Momokazu Gotoh
Keyword(s):  
Prostate Cancer ◽  
Androgen Receptor ◽  
Primary Outcome ◽  
Progression Free Survival ◽  
Intraductal Carcinoma ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival ◽  
Carcinoma Of The Prostate ◽  
Castration Resistant ◽  
Time Of Administration

150 Background: This study aimed to investigate the efficacy of docetaxel and androgen receptor axis-targeted (ARAT) agents in castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P). Methods: We retrospectively identified 311 CRPC patients from June 2002 to February 2016. All patients were initially administered with androgen deprivation therapy (ADT), followed by docetaxel or ARAT (abiraterone or enzalutamide) after progressing to CRPC. The primary outcome of interest was overall survival (OS) from the time of CRPC diagnosis and progression-free survival (PFS) from the time of administration of docetaxel or ARAT. Results: IDC-P was found in 180 of 311 patients. The median OS was 33.4 and 64.0 months with and without IDC-P, respectively (hazards ratio [HR], 2.14; P < 0.001). For the first treatment for CRPC, docetaxel was administered to 71 and 50 patients with and without IDC-P, respectively, with a median OS of 30.4 and 64.0 months, respectively (HR, 2.62; P < 0.001). ARAT was administered to 109 and 81 patients with and without IDC-P, respectively, with a median OS of 45.0 and 69.9 months, respectively (HR, 1.84; P = 0.017). Regarding patients with IDC-P, the OS in patients who were administered with ARAT was longer than that in those administered with docetaxel (HR, 0.58; P = 0.008). The median PFS was 7.5 and 12.1 months with and without IDC-P, respectively (HR, 1.36; P = 0.03). Multivariate analysis showed that the prognostic factors for OS were the presence of IDC-P (HR, 1.91; P < 0.001), and administration of ARAT (HR, 0.66; P = 0.02). Conclusions: The presence of IDC-P is an independent prognostic factor for OS and PFS in CRPC patients. ARAT may prolong OS in CRPC patients with IDC-P.

Sign in / Sign up

Export Citation Format

Share Document